The purpose of this study is to collect information on the: - general information of a group of people such as their age, sex - clinical information of the patients such as any other illness before having COVID 19. - the number of COVID-19 patients who meet and follow the most up to date World Health Organization (WHO) recommendations for medication to treat COVID-19 (such as version 14, published 10Nov2023) compared to Kingdom of Bahrain national recommendations - adult COVID-19 patients' health care resource use and outcomes within the 28-day period In adult patients with COVID-19 who have been prescribed nirmatrelvir and ritonavir treatment.This study will be conducted in the Kingdom of Bahrain. The study will captureinformation of the adult COVID-19 outpatients and inpatients who have been prescribednirmatrelvir, ritonavir treatment and those not treated with nirmatrelvir, ritonavir.This study will have about 3000 patients treated with Paxlovid™ therapy and 1000 werenot. The study will involve collection of patient information from medical records. Theinformation collected can be either from papers or from computers.The study will include patient information of those who: - had COVID-19 infection during the study period from 16 February 2022 to 30 November 2022. - are 18 years of age or older. This study will help to inform decision-making on use of Paxlovid at the national level.
Not Provided
Drug: nirmatrelvir, ritonavir
Patients receiving Nirmatrelvir; Ritonavir (PAXLOVID)
Other: Controls
Patients who do not receive Nirmatrevir/ritonavir (Paxlovid)
Inclusion Criteria:
Patients must meet all of the following inclusion criteria to be eligible for inclusion
in the study:Age 18 years and older Patients with a diagnosis of COVID-19 whose
information can be extracted from the I-Seha database
Exclusion Criteria:
There are no exclusion criteria for this study.
Pfizer Gulf FZ
Busaiteen, Bahrain
Pfizer CT.gov Call Center, Study Director
Pfizer